Participation in Trials of Rare Cancers
NCI-designated Cancer Centers play a key national role in developing new therapies in rare cancers. Centers are expected to lead, and/or participate in, NCI's National Clinical Trials Network trials, including studies of rare cancers. While Centers, through their Protocol Review and Monitoring System (PRMS), have the authority to close trials for poor accrual, exceptions should be made for trials involving rare diseases.
NCI–designated Cancer Center Logos
NCI–designated Cancer Centers and NCI–designated Comprehensive Cancer Centers
will be allowed to use the NCI Cancer Center logo, appropriate to their designation,
in the promotion, advocacy, educational, and other related activities of the
individual cancer center. Cancer Centers and Comprehensive Cancer Centers are not allowed to
use the NCI logo.
Click to see the
full policy. —posted 11/05/2013